BridgeBio Pharma (BBIO) shares ticked up after positive data from a late-stage trial testing encaleret for treating a genetic ...
The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...
By Padmanabhan Ananthan (Reuters) -BridgeBio Pharma's experimental drug for a rare genetic condition that causes low blood calcium met all the main and secondary goals in a late-stage study, the ...
Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...
The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - ...
BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another ...
The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...
BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...
BridgeBio Pharma (BBIO) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is -$0.78 (+9.3% ...
The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...
Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82. The announcement from BridgeBio ...
BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback